Core Points - The report details the fundraising and usage status of Hubei Huqiang Technology Co., Ltd. for the first half of 2025, ensuring compliance with regulatory requirements [1][5] - The total amount raised through the public offering was approximately RMB 3.02 billion, with a net amount of RMB 2.81 billion after deducting issuance costs [1][3] - As of June 30, 2025, the company has utilized RMB 1.51 billion of the raised funds, with a remaining balance of RMB 1.44 billion [1][4] Fundraising Overview - The company issued 86,206,200 shares at a price of RMB 35.09 per share, resulting in total fundraising of RMB 3,024,975,558.00 [1] - The funds were received on December 1, 2021, and have been audited by Da Xin Accounting Firm [1][2] Fund Usage - Cumulative usage of the raised funds as of June 30, 2025, was RMB 1,507,281,356.38, with RMB 264,318,264.54 used in the current year [1][4] - The remaining balance in the special account for the raised funds was RMB 1,435,171,906.68 [1][4] Fund Management - The company has established a management system for the raised funds, ensuring they are stored in a special account and used according to regulations [1][3] - A tripartite supervision agreement was signed with banks and the sponsor, ensuring compliance with fund management [1][3] Cash Management - The company has utilized part of the temporarily idle raised funds for cash management, with an amount of RMB 1,287,623,759.08 invested in structured deposits and other financial products [3][4] - The maximum amount for cash management is capped at RMB 2 billion, with a focus on low-risk financial products [3][4] Project Adjustments - The company has adjusted the implementation plans for several fundraising projects, including reducing the investment for the "New Nuclear Biological Emergency Rescue Protective Equipment Industrialization Production Base Project" from RMB 772 million to RMB 387.54 million [5][6] - New projects have been added, such as the "New Drug Delivery Device and Packaging Materials R&D and Industrialization Project," with a total investment of RMB 397.53 million [5][6] Compliance and Reporting - The company has confirmed that there are no discrepancies between the disclosed fundraising usage and the actual usage, ensuring timely and accurate reporting [5][6] - There are no instances of using raised funds for non-compliant purposes or for repaying bank loans [5][6]

Group 1 - The core viewpoint of the report is to summarize the sponsorship and regulatory compliance of Hubei Huqiang Technology Co., Ltd. during its initial public offering (IPO) on the Sci-Tech Innovation Board [1] - The issuer, Hubei Huqiang Technology Co., Ltd., has a registered capital of 344.5 million yuan and was listed on December 6, 2021 [1] - The report outlines the responsibilities of the sponsor, Huatai United Securities, including due diligence, document preparation, and compliance with regulatory requirements [1][3] Group 2 - The net amount raised from the IPO was 2.8121508 billion yuan, allocated to various projects including the "New Nuclear Biochemical Emergency Rescue Protection Equipment Industrialization Production Base Project" [4] - As of 2024, the balance of the special account for raised funds was 1.69612742 billion yuan, which includes idle funds used for cash management [4] - The sponsor has issued independent opinions on the use of raised funds for the years 2021, 2022, and 2023, confirming compliance with relevant regulations and no violations in fund usage [6][7][13] Group 3 - The report details the continuous supervision activities conducted by the sponsor, including on-site inspections and reviews of the issuer's governance and fund usage [3][4] - The sponsor has issued 24 verification opinions during the supervision period, with no disapprovals noted [8] - The issuer has been responsive to regulatory inquiries and has made necessary corrections regarding financial reporting and fund management [10][11]